Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publication Year: 2024

Authors & Co-authors:  Hoffman Risa M RM Brummel Sean S Ziemba Lauren L Chinula Lameck L McCarthy Katie K Fairlie Lee L Jean-Philippe Patrick P Chakhtoura Nahida N Johnston Ben B Krotje Chelsea C

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Publication Year: 2021

Authors & Co-authors:  Lockman Brummel Ziemba Stranix-Chibanda McCarthy Coletti Jean-Philippe Johnston Krotje Fairlie

Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.

Journal: The lancet. HIV

Publication Year: 2023

Authors & Co-authors:  Chinula Ziemba Brummel McCarthy Coletti Krotje Johnston Knowles Moyo Stranix-Chibanda

Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.

Journal: The lancet. HIV

Publication Year: 2023

Authors & Co-authors:  Brooks Kiser Ziemba Ward Rani Cressey Masheto Cassim Deville Ponatshego